Related Experiment Video
Updated: Oct 15, 2025

05:13
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
398
An Update on Perinatal Cannabis Use
Catherine Grandy1, Jennifer Donnan1, Lisa Bishop1
1School of Pharmacy, Memorial University of Newfoundland, St. John's, NL.
Summary
Cannabis use during pregnancy is a growing concern. Evidence-based guidance helps healthcare providers support patients and minimize potential harms of prenatal cannabis exposure for children.
Area of Science:
- Obstetrics and Gynecology
- Public Health
- Cannabis Research
Background:
- Legalization of non-medical cannabis has increased questions about its use during pregnancy.
- Prenatal cannabis exposure poses potential risks to fetal development and child outcomes.
- Healthcare providers need updated information to address patient concerns and guide care.
Purpose of the Study:
- To review the literature on cannabis use in pregnancy.
- To identify high-risk populations and predictors of use.
- To inform obstetrical care providers with evidence-based strategies.
Main Methods:
- Literature review and synthesis of existing research on prenatal cannabis exposure.
- Analysis of factors influencing cannabis use decisions during pregnancy.
- Examination of documented short- and long-term infant and child outcomes.
Main Results:
- Identifies specific demographic and psychosocial factors associated with higher rates of cannabis use.
- Explores motivations for continued or cessation of cannabis use during pregnancy.
- Summarizes known adverse effects on neurodevelopment and behavior in exposed offspring.
Conclusions:
- Healthcare providers can mitigate risks by understanding patient use patterns and providing evidence-based counseling.
- Informed decision-making is crucial for optimizing care for pregnant individuals using cannabis.
- Further research is needed to fully elucidate long-term impacts and effective interventions.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
417
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
417
Teratogenicity
3.0K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.0K

